Chien-Min Hung

Chien-Min Hung

Auto-generated profile, based on publicly available information

Chien-Min Hung

Pharmaceutical Research & Development, Microbio Co, Ltd, Taipei, Taiwan

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 April 2021 in Science Advances
Verified
Journal Article
Open access
PDF file
CHChien-Min Hung
Chien-Min Hung
PLPortia S. Lombardo
Portia S. Lombardo
NMNazma Malik
Nazma Malik
SBSonja N. Brun
Sonja N. Brun
KHKristina Hellberg
Kristina Hellberg
RSReuben J. Shaw
Reuben J. Shaw
Parkin is phosphorylated on Ser 108 in ACT domain by AMPK/ULK1 signaling within minutes of mitochondrial stress.

2 June 2022 in JID Innovations
Verified
Journal Article
Open access
CLChing-Wen Lin
Ching-Wen Lin
CCChih-Chiang Chen
Chih-Chiang Chen
WHWen-Yen Huang
Wen-Yen Huang
YCYen-Yu Chen
Yen-Yu Chen
SCShiou-Ting Chen
Shiou-Ting Chen
SCShun-Cheng Chang
Shun-Cheng Chang
Diabetic wounds exhibit chronic inflammation and delayed tissue proliferation or remodeling, mainly owing to prolonged proinflammatory (M1) macrophage activity and defects in transition to prohealing/proremodeling (M2a/M2c; CD206+ and/or CD163+) macrophages. We found that topical treatment with ON101, a plant-based potential therapeutic for diabetic foot ulcers, increased M2c-like (CD163+ and CD206+) cells and suppressed M1-like cells, altering the inflammatory gene profile in a diabetic mouse model compared with that in the controls. An in vitro macrophage-polarizing model revealed that ON101 directly suppressed CD80+ and CD86+ M1-macrophage polarization and M1-associated proinflammatory cytokines at both protein and transcriptional levels. Notably, conditioned medium collected from ON101-treated M1 macrophages reversed the M1-conditioned medium‒mediated suppression of CD206+ macrophages. Furthermore, conditioned medium from ON101-treated adipocyte progenitor cells significantly promoted CD206+ and CD163+ macrophages but strongly inhibited M1-like cells. ON101 treatment also stimulated the expression of GCSF and CXCL3 genes in human adipocyte progenitor cells. Interestingly, treatment with recombinant GCSF protein enhanced both CD206+ and CD163+ M2 markers, whereas CXCL3 treatment only stimulated CD163+ M2 macrophages. Depletion of cutaneous M2 macrophages inhibited ON101-induced diabetic wound healing. Thus, ON101 directly suppressed M1 macrophages and facilitated the GCSF- and CXCL3-mediated transition from M1 to M2 macrophages, lowering inflammation and leading to faster diabetic wound healing.

30 July 2024 in Gut Microbes
Verified
Journal Article
Open access
PLPei-Jung Lee
Pei-Jung Lee
CHChien-Min Hung
Chien-Min Hung
AYAi-Jen Yang
Ai-Jen Yang
CHCheng-Yu Hou
Cheng-Yu Hou
HCHung-Wen Chou
Hung-Wen Chou
WCWan-Jiun Chen
Wan-Jiun Chen
Cancer immunotherapy has been regarded as a promising strategy for cancer therapy by blocking immune checkpoints and evoking immunity to fight cancer, but its efficacy seems to be heterogeneous among patients. Manipulating the gut microbiota is a potential strategy for enhancing the efficacy of immunotherapy. Here, we report that MS-20, also known as "Symbiota®", a postbiotic that comprises abundant microbial metabolites generated from a soybean-based medium fermented with multiple strains of probiotics and yeast, inhibited colon and lung cancer growth in combination with an anti-programmed cell death 1 (PD1) antibody in xenograft mouse models. Mechanistically, MS-20 remodeled the immunological tumor microenvironment by increasing effector CD8+ T cells and downregulating PD1 expression, which were mediated by the gut microbiota. Fecal microbiota transplantation (FMT) from mice receiving MS-20 treatment to recipient mice increased CD8+ T-cell infiltration into the tumor microenvironment and significantly improved antitumor activity when combined with anti-PD1 therapy. Notably, the abundance of Ruminococcus bromii, which increased following MS-20 treatment, was positively associated with a reduced tumor burden and CD8+ T-cell infiltration in vivo. Furthermore, an ex vivo study revealed that MS-20 could alter the composition of the microbiota in cancer patients, resulting in distinct metabolic pathways associated with favorable responses to immunotherapy. Overall, MS-20 could act as a promising adjuvant agent for enhancing the efficacy of immune checkpoint-mediated antitumor therapy.

8 January 2024 in Food Science & Nutrition
Verified
Journal Article
Open access
CHChien‐Min Hung
Chien‐Min Hung
WCWen‐Cheng Chu
Wen‐Cheng Chu
WHWen‐Yen Huang
Wen‐Yen Huang
PLPei‐Jung Lee
Pei‐Jung Lee
WKWen‐Chih Kuo
Wen‐Chih Kuo
WCWan‐Jiun Chen
Wan‐Jiun Chen
A safety evaluation was performed of Symbiota®, which is made by a proprietary anaerobic fermentation process of soybean with multistrains of probiotics and a yeast. The battery of genotoxicity studies showed that Symbiota® has no genotoxic effects. Safety and tolerability were further assessed by acute or repeated dose 28‐ and 90‐day rodent studies, and no alterations in clinical observations, ophthalmological examination, blood chemistry, urinalysis, or hematology were observed between the control group and the different dosing groups (1.5, 5, and 15 mL/kg/day). There were no adverse effects on specific tissues or organs in terms of weight and histopathology. Importantly, the Symbiota® treatment did not perturb hormones and other endocrine‐related endpoints. Of note, the No‐Observed‐Adverse‐Effect‐Level was determined to be 15 mL/kg/day in rats. Moreover, a randomized, double‐blind, placebo‐controlled clinical trial was recently conducted with healthy volunteers who consumed 8 mL/day of placebo or Symbiota® for 8 weeks. Only mild adverse events were reported in both groups, and the blood chemistry and blood cell profiles were also similar between the two groups. In summary, this study concluded that the oral consumption of Symbiota® at 8 mL/day by the general population does not pose any human health concerns.